|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:antidote
|
gptkb:flumazenil
|
|
gptkbp:ATCCode
|
N05CD02
|
|
gptkbp:availableOn
|
tablet form
|
|
gptkbp:brand
|
gptkb:nitrazepam
|
|
gptkbp:broadcastOn
|
Schedule IV (US)
Schedule 4 (UK)
|
|
gptkbp:CASNumber
|
146-22-5
|
|
gptkbp:cause
|
dependence
withdrawal symptoms
|
|
gptkbp:chemicalFormula
|
C15H11N3O3
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
sleep apnea syndrome
severe hepatic insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
yes
|
|
gptkbp:drugClass
|
gptkb:benzodiazepine
|
|
gptkbp:eliminatedIn
|
renal
hepatic
|
|
gptkbp:halfLife
|
16-38 hours
|
|
gptkbp:interactsWith
|
gptkb:beer
opioids
other CNS depressants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Sanofi
1965
|
|
gptkbp:mechanismOfAction
|
enhances GABAergic transmission
|
|
gptkbp:notRecommendedFor
|
children
pregnant women
elderly (caution)
|
|
gptkbp:overdoseSymptoms
|
coma
respiratory depression
excessive sedation
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
drowsiness
muscleRelaxation
|
|
gptkbp:tradeNameIn
|
gptkb:Australia
gptkb:UK
|
|
gptkbp:usedFor
|
insomnia
sedation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mogadon
|